Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Present and future therapy options in IgA-nephropathy.

J Floege1, F Eitner

  • 1Department of Nephrology and Immunology, University of Aachen - Germany. jeurgen.floege@rwth-aachen.de

Journal of Nephrology
|October 26, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time-dependent lipid profile inversely associates with mortality in hemodialysis patients - independent of inflammation/malnutrition.

Journal of internal medicine·2021
Same author

Heart failure in advanced chronic kidney disease: treatment rationale.

Herz·2021
Same author

[Immunoglobulin A nephropathy].

Der Internist·2019
Same author

[What is certain in the treatment of glomerulonephritis?]

Der Internist·2018
Same author

[Choosing wisely recommendations in nephrology].

Der Internist·2017
Same author

[Anticoagulation in patients with chronic kidney disease : Recommendations from the working group "Heart-Kidney" of the German Cardiac Society and the German Society of Nephrology].

Der Internist·2017
Same journal

Correction to: Abdominal arterial calcification profile in kidney transplant candidates: a comparison between patients with autosomal dominant polycystic kidney disease and those with other causes of kidney failure.

Journal of nephrology·2026
Same journal

Lessons for the Clinical Nephrologist. Not to see the forest for the trees: the diagnostic challenge with valproic acid-induced Fanconi-like proximal tubulopathy.

Journal of nephrology·2026
Same journal

Longitudinal trajectories in multidomain frailty among patients with chronic kidney disease.

Journal of nephrology·2026
Same journal

Correction to: Association between primary care physician-nephrologist collaboration and clinical outcomes in patients with stage 5 chronic kidney disease: a JOINT-KD cohort study.

Journal of nephrology·2026
Same journal

Improving eGFR estimation in diabetic populations: insights from real-world data.

Journal of nephrology·2026
Same journal

Barriers delaying treatment in cases at risk of crush syndrome in major disasters: Kahramanmaraş earthquake experience.

Journal of nephrology·2026
See all related articles

IgA-nephropathy (IgAN) treatments have advanced, with corticosteroids and combination therapies showing promise for specific patient groups. Optimal supportive care is recommended first, reserving immunosuppression for severe cases.

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Evidence for treating progressive IgA-nephropathy (IgAN) has improved.
  • Two randomized controlled trials (RCTs) evaluated therapeutic approaches.

Purpose of the Study:

  • To review current therapeutic strategies for IgAN.
  • To assess the efficacy of immunosuppressive therapy versus supportive care.
  • To explore novel therapeutic targets.

Main Methods:

  • Review of recent studies, including RCTs.
  • Analysis of treatment outcomes based on renal function and proteinuria.
  • Discussion of emerging therapeutic strategies.

Main Results:

  • Corticosteroids may prevent renal failure in IgAN patients with GFR > 70 ml/min.

Related Experiment Videos

  • Combination therapy (cyclophosphamide, azathioprine, corticosteroids) effective for impaired renal function.
  • Superiority of immunosuppression over aggressive supportive care (ACE-inhibitors, ARBs, smoking cessation) not firmly established.

    • Conclusions:

    • Prioritize aggressive supportive therapy for IgAN.
    • Limit immunosuppressive therapy to patients with persistent proteinuria (>1 g/day) or declining GFR.
    • Platelet-derived growth factor antagonism is a promising novel therapeutic alternative.
    • Development of IgAN animal models is crucial for advancing novel therapies.